This strategy targets the upstream transcriptional control of cholesterol homeostasis by directly activating SREBF2 (SREBP-2) to simultaneously enhance ABCA1 expression while overriding miR-33-mediated suppression. Unlike antisense approaches that block miR-33 post-transcriptionally, this mechanism leverages pharmacological SREBF2 super-activation to create a transcriptional flood that overwhelms miR-33 inhibitory capacity through sheer mRNA abundance. Small molecule activators or modified LXR agonists would target SREBF2's proteolytic processing machinery, forcing constitutive nuclear translocation and DNA binding even under cholesterol-replete conditions. This approach exploits the co-transcriptional relationship between SREBF2 and miR-33, where massive SREBF2 activation paradoxically produces both increased ABCA1 mRNA and increased miR-33, but the stoichiometric imbalance favors net ABCA1 protein production. The molecular rationale centers on saturating RISC complexes with excess miR-33 while simultaneously providing surplus ABCA1 transcripts that escape silencing.

This strategy targets the upstream transcriptional control of cholesterol homeostasis by directly activating SREBF2 (SREBP-2) to simultaneously enhance ABCA1 expression while overriding miR-33-mediated suppression. Unlike antisense approaches that block miR-33 post-transcriptionally, this mechanism leverages pharmacological SREBF2 super-activation to create a transcriptional flood that overwhelms miR-33 inhibitory capacity through sheer mRNA abundance. Small molecule activators or modified LXR agonists would target SREBF2's proteolytic processing machinery, forcing constitutive nuclear translocation and DNA binding even under cholesterol-replete conditions. This approach exploits the co-transcriptional relationship between SREBF2 and miR-33, where massive SREBF2 activation paradoxically produces both increased ABCA1 mRNA and increased miR-33, but the stoichiometric imbalance favors net ABCA1 protein production. The molecular rationale centers on saturating RISC complexes with excess miR-33 while simultaneously providing surplus ABCA1 transcripts that escape silencing. Additionally, SREBF2 hyperactivation would upregulate the entire cholesterogenic program including HMG-CoA reductase and LDLR, creating a cellular environment primed for maximal cholesterol efflux capacity. In APOE4-expressing microglia and astrocytes, this would generate hyper-lipidated APOE4 particles with enhanced structural stability and Aβ binding affinity. The therapeutic advantage lies in leveraging the cell's natural transcriptional machinery rather than introducing synthetic oligonucleotides, potentially reducing off-target effects while achieving more robust and sustained ABCA1 upregulation. This strategy could prove particularly effective in brain regions with high SREBF2 expression, creating localized zones of enhanced APOE4 lipidation capacity.